Verve Therapeutics
VERV
VERV was delisted on the 24th of July, 2025.
157 hedge funds and large institutions have $1.04B invested in Verve Therapeutics in 2023 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 67 increasing their positions, 26 reducing their positions, and 20 closing their positions.
158% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 26
120% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 20
23% more capital invested
Capital invested by funds: $847M → $1.04B (+$195M)
18% more funds holding
Funds holding: 133 → 157 (+24)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2.24% less ownership
Funds ownership: 100.25% → 98% (-2.2%)
11% less call options, than puts
Call options by funds: $3.63M | Put options by funds: $4.06M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$24.8M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$22.6M |
| 3 |
AI
Alphabet Inc
Mountain View,
California
|
+$22.3M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$17.9M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$15.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$38.8M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$7.87M |
| 3 |
JP Morgan Chase
New York
|
-$5.55M |
| 4 |
AG
Artal Group
Luxembourg
|
-$3.98M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$3.78M |
VERV Hedge Fund Activity: Q4 2023 in Review
157 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q4 2023, worth a combined $1.04B — up 23% from $847M a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new VERV positions and 20 closed out — a net gain of 24 holders — while 67 added to existing stakes and 26 trimmed.
The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $24.8M. The largest seller was Fidelity Investments, cutting an estimated $38.8M.
- 157 institutional investors held Verve Therapeutics (VERV) as of Q4 2023, up from 133 in Q3 2023.
- Funds reported $1.04B of Verve Therapeutics stock for Q4 2023, up 23% quarter-over-quarter.
- 44 funds opened new Verve Therapeutics positions in Q4 2023 and 20 closed out, a net change of +24 holders.
- The largest Verve Therapeutics buyer in Q4 2023 was Novo Holdings A/S, an estimated $24.8M added.
- The largest Verve Therapeutics seller in Q4 2023 was Fidelity Investments, an estimated $38.8M sold.
Based on aggregated 13F filings for Q4 2023.